| Outcome Measures: |
Primary: Peak Oxygen Consumption (VO2 Peak), Subjects' peak oxygen consumption (VO2 peak) will be tested on a stationary bike before and after 3 months of study medication or placebo., Baseline and 3 months | Secondary: Oxygen Uptake Kinetics Steady State Tau, Time to steady state oxygen consumption will be assessed in subject before and after 3 months of study medication or placebo., Baseline and 3 months|Change From Baseline in Arterial Stiffness, Pulse wave velocity will be measured via sphygmocor before and after 3 months of study medication or placebo., Baseline and 3 months|Change From Baseline in Peak Dilation of Brachial Artery Diameter, Change in the response of the brachial artery to hyperemia will be assessed before and after 3 months of study medication or placebo., Baseline and 3 months|Change in (Non-invasively Measured) Deoxygenated Hemoglobin Concentration in the Vastus Lateralis During Exercise, Deoxygenated hemoglobin concentration will be measured using near-infrared spectroscopy during sub-maximal exercise before and after 3 months of study drug administration., Baseline and 3 months|Echocardiographic Measures - Circumferential Strain, Potential change in cardiac function will be assessed by echocardiography before and after 3 months of study medication or placebo., Baseline and 3 months|Echocardiographic Measures - Longitudinal Strain, Potential change in cardiac function will be assessed by echocardiography before and after 3 months of study medication or placebo., Baseline and 3 months|Echocardiographic Measures - Stroke Volume, Potential change in cardiac function will be assessed by echocardiography before and after 3 months of study medication or placebo., Baseline and 3 months|Echocardiographic Measures - Mitral Valve E Wave Velocity, Potential change in cardiac function will be assessed by echocardiography before and after 3 months of study medication or placebo., Baseline and 3 months|Echocardiographic Measures - Mitral Valve E:A Wave Velocity, Potential change in cardiac function will be assessed by echocardiography before and after 3 months of study medication or placebo., Baseline and 3 months|Echocardiographic Measures - Mitral Valve Deceleration Time, Potential change in cardiac function will be assessed by echocardiography before and after 3 months of study medication or placebo., Baseline and 3 months|Echocardiographic Measures - Septal E', Potential change in cardiac function will be assessed by echocardiography before and after 3 months of study medication or placebo., Baseline and 3 months|Echocardiographic Measures - Septal E:E', Potential change in cardiac function will be assessed by echocardiography before and after 3 months of study medication or placebo., Baseline and 3 months|Echocardiographic Measures - Lateral E', Potential change in cardiac function will be assessed by echocardiography before and after 3 months of study medication or placebo., Baseline and 3 months|Echocardiographic Measures - Lateral E:E', Potential change in cardiac function will be assessed by echocardiography before and after 3 months of study medication or placebo., Baseline and 3 months
|
